{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T14:28:54Z","timestamp":1782224934127,"version":"3.54.5"},"reference-count":11,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1128\/aac.01646-16","type":"journal-article","created":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T02:18:28Z","timestamp":1471918708000},"page":"6989-6990","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["Eravacycline Is Active against Bacterial Isolates Expressing the Polymyxin Resistance Gene\n            <i>mcr-1<\/i>"],"prefix":"10.1128","volume":"60","author":[{"given":"Corey","family":"Fyfe","sequence":"first","affiliation":[{"name":"Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Close","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Nordmann","sequence":"additional","affiliation":[{"name":"Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Department of Medicine, INSERM European Unit, Paris, France, University of Fribourg, Fribourg, Switzerland, and University of Lausanne, University Hospital Centre, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Dumas","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trudy H.","family":"Grossman","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00424-7"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00066-16"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01267-16"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw240"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00463-6"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00177-16"},{"key":"e_1_3_1_8_2","article-title":"Methods for dilution of antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014tenth edition","author":"CLSI","year":"2015","unstructured":"CLSI. 2015. Methods for dilution of antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014tenth edition. CLSI document M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.","journal-title":"CLSI document M07-A10"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11434-016-1086-y"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00444-16"},{"key":"e_1_3_1_11_2","volume-title":"CLSI document","author":"CLSI","year":"2016","unstructured":"CLSI. 2016. Performance standards for antimicrobial susceptibility testing; twenty-six informational supplement. CLSI document. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_1_12_2","volume-title":"Prescribing information","author":"Wyeth Pharmaceuticals","year":"2016","unstructured":"Wyeth Pharmaceuticals. 2016. Tygacil\u2014tigecycline injection, powder, lyophilized, for solution. Prescribing information. Wyeth Pharmaceuticals, Philadelphia, PA."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01646-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01646-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:37:07Z","timestamp":1645475827000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01646-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":11,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1128\/AAC.01646-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.01646-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"2016-10-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}